Woman and Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary efficacy objective is to evaluate whether rivaroxaban, in doses of 10 mg or 20 mg, is superior to acetylsalicylic acid (ASA) 100 mg in the prevention of the primary efficacy outcome (i.e. fatal or non-fatal symptomatic recurrent venous thromboembolism). The principal safety objective is to document the incidence of the principal safety outcome (i.e. major bleeding).
Inclusion criteria
- Long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism